Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppression
The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and engraftment:
Efficacy:
BioTrinity is attended by an ever-evolving international audience of c.850 delegates, comprising a mix of academic entrepreneurs, early stage and emerging life sciences R&D companies, funders & investors, big pharma teams, charities & research bodies, government, regulatory bodies, along with professional services and expert supporters to the industry.
This year’s event will feature a diverse global audience, international market showcases, dedicated investor networking, and presentations from the most promising life sciences companies.
About RxCelerate
The RxCelerate group provides a platform for out-sourced drug discovery and development services and has a client base ranging from virtual biotech companies to multinational pharmaceutical companies. We design and deliver complete drug development programmes and project management for our clients from inception through to Phase II clinical studies.
This role will support the growth and visibility of RxCelerate and its affiliates by contributing to both business development activities and marketing and communications initiatives.
The Role
LONDON, UK – February 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).
Nuclera is a venture-backed biotech company headquartered in Cambridge, UK with significant operations in Boston, USA. Nuclera’s mission is to accelerate discovery by enabling rapid, easy access to functional proteins essential for drug discovery research. Our eProtein Discovery™ benchtop system accelerates protein expression and purification optimization in research labs.
Senior Bioinformatician - Translational & Clinical Development UK (London) / BE (Gent)
BioLizard (“The Lizards”) is a leading bioinformatics consultancy that partners with biotech and pharma organizations to bridge biology, data, and AI. Our mission is to unlock insights that accelerate scientific innovation and clinical translation.
EMBL's European Bioinformatics Institute (EMBL-EBI) is seeking talented and highly-motivated scientists to join its Faculty and develop their own independent research group. We welcome applicants from across the whole field of computational biology, in particular those working at the interface of artificial intelligence and biology. Women, who are under-represented in our Faculty, are especially encouraged to apply.
About us
Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential.
Using a simple 3-step process of media changes and cell passaging – these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, thereby saving you valuable time.
We are pleased to announce the shortlist for the One Nucleus Awards 2026.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders.
Best Therapeutic R&D Programme of the Year:
⭐Resolution Therapeutics
⭐Serenatis Bio
⭐Trimtech Therapeutics Ltd
Best Use of Emerging Technology of the Year:
⭐Ignota Labs
⭐Constructive Bio
⭐Nuclera Ltd